Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for 4 medicines.
- Cannabidiol (Epidyolex®) in combination with other antiepileptic medicines to treat seizures that occur with a genetic disorder called tuberous sclerosis complex (TSC). It can be used in adults, adolescents and children of at least 2 years of age.
- Clostridium botulinum neurotoxin type A (Xeomin®) is used in children and adolescents aged 2 to 17 years and weighing more than 12 kg to treat chronic drooling (sialorrhea) due to neurological / neurodevelopmental disorders.
- Dabigatran etexilate (Pradaxa®) to treat blood clots and prevent the re-occurrence of blood clots in the veins or in the blood vessels of the lungs. It can be used in children and adolescents aged 8 to 17 years.
- Rivaroxaban (Xarelto®) for use in full-term newborn babies, infants and toddlers, children and adolescents aged under 18 years to treat blood clots and to prevent the re-occurrence of blood clots in the veins or in the blood vessels of the lungs.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.